(Q28343618)

2

0 references

S Bauer

3

0 references

C Sachse

4

0 references

P Güzelbey

5

0 references

Z Ongen

6

0 references

M Nacak

7

0 references

I Roots

British Journal of Clinical Pharmacology

8

0 references

language of work or name

English

0 references

publication date

September 1999

0 references

published in

0 references

volume

48

0 references

issue

3

0 references

page(s)

409-15

0 references

cites work

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Biochemistry and molecular biology of the human CYP2C subfamily

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Interethnic variation of drug metabolism

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Allelic and functional variability of cytochrome P4502C9.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings]

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

2 June 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.1999.00012.X

Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.1999.00012.X

Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.1999.00012.X

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.1999.00012.X

Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations

21 January 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

27 November 2018

https://api.crossref.org/works/10.1046%2FJ.1365-2125.1999.00012.X

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014334

Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans

27 November 2018

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study

1 reference

12 December 2020

Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001)

1 reference

12 December 2020

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

12 December 2020

Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4

1 reference

12 December 2020

Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin

1 reference

12 December 2020

10.1046/J.1365-2125.1999.00012.X

Identifiers

DOI

1 reference

release_nhwrlw5yafgx7exix4ihirnibi

Fatcat ID

0 references

1 reference

1 reference

PubMed publication ID

10510154

1 reference